Newsletter

With a TINY FLOAT of just under 2 million shares, 

SNDY shares could soon be ready for LIFT OFF!

Greetings Traders,

Hurry and add SNDY to your immediate radar for tomorrow's trading day.

This is a company that is making huge strides in the early detection of breast cancer and is trading at only 9 cents with a very LOW FLOAT!

Low-float stocks tend to be much more volatile than stocks with heavier floats which means SNDY may be very attractive at these levels. 

About 1 in 8 U.S. women will develop invasive breast cancer over the course of her lifetime. This makes the need for early detection extremely important. 

With no cure in sight, finding the cancer early is the best way to survive. 

SNDY has an endoscopy system that can make early detection a lot easier!

The stock could be GROUND-FLOOR treasure on the brink of discovery!

Shares saw an impressive 125% jump today on relatively low volume. This was one of the biggest moves SNDY has seen in months and could be indicative of bigger things to follow.  

There is a reason why many savvy traders pay special attention to these low float stocks. Simply put, the "float" of a stock is the number of shares available to the public for trading. 

These stocks are capable of seeing gains in the hundreds and sometimes thousands of percents quickly due to their limited availability of shares. 

Case in point with SNDY accumulating a massive gain of over 100% just today!

Healthcare is a trillion dollar industry and leading hospitals and clinics are already using SNDY's endoscopic instruments to perform numerous minimally invasive endoscopic procedures.

Now that technology is available to the breast care medical community, this is what could give SNDY a distinct edge in the health care arena!

About the Company:

SNDY is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. 

Backed by technical support, the company's sales team can help make the right buying decisions for the hospital, surgery center, or physician office.

SNDY's MammoView Breast Endoscopy System employs advanced microendoscopes and optical technology to give physicians sharp, clear images of the milk ducts, where the majority of the breast cancers arise. Physicians can clearly see the boundary between healthy and abnormal tissue.

The system can: 

Distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods.

Perform related intraductal procedures with direct visualization of tissues.

Complement existing diagnosis and treatment options with direct endoscopic observation.

This Mammary ductoscopy is designed to provide physicians the means to detect, diagnose, and treat breast cancer years before surgery, physical exams or other external imaging can reveal evidence of the disease.

The American Cancer Society's estimates in the United States that about 246,660 new cases of invasive breast cancer will be diagnosed in women this year! 

It is the most common cancer in women worldwide. As scary as it is, early detection can make the disease a lot less grueling and can be what saves the person's life. 

SNDY looks like just a blip on Wall Street's screen right now but if more people discover what the company is up to, the potential gains to come could be beyond imagination... especially with such a tiny float!

You might want to start your own research right away by visiting the company's page: http://www.solosendoscopy.com

SNDY may be one of the most profitable stocks we've seen in a long time at these levels..

Could today's gains be just the beginning? 

We are engaged in the business of marketing and advertising companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Pennystocktitans.com sponsored advertisements do not purport to provide an analysis of any company's financial position, operations or prospects and this is not to be construed as a recommendation by Pennystocktitans.com or an offer or solicitation to buy or sell any securities.

None of the owners of Pennystocktitans.com, or any of its members, officers, directors, contractors or employees is a licensed broker-dealer, account representative, market maker, investment banker, investment advisor, analyst or underwriter. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Pennystocktitans.com makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors.

Pennystocktitans.com makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should use the information provided by us regarding the profiled companies as a starting point for additional independent research on the companies profiled or discussed in order to allow the viewer to form his or her own opinion regarding investing in the securities of such companies. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and Pennystocktitans.com  has no obligation to update any of the information provided, nor is it responsible for errors and omissions.

From time to time certain content in our releases or website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our releases and website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap or penny stock market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled in our releases or on our website may not have approved certain or any statements within the release or website. Pennystocktitans.com  encourages viewers to supplement the information obtained from any release or our website with independent research and other professional advice. By accessing, viewing, or using our website or communications originating from our website or any release therein, you agree that Pennystocktitans.com, its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that Pennystocktitans.com, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

Pennystocktitans.com uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. You agree to hold Pennystocktitans.com, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur arising out of the use of our website or the information in our press releases, profiles and opinions. You agree that use of our website is at your sole risk. Pennystocktitans.com  disclaims all warranties of any kind, express or implied. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the SEC. The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov and/or then FINRA at: www.finra.org . In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/investors/index.htm.

Questions regarding any information contained in this website may be sent to info@pennystocktitans.com To review our complete disclaimer and additional information, please visit www.pennystocktitans.com

COMPANY SPECIFIC DISCLAIMER

Some of the content in this release may contain forward-looking information within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the profiled companies and the value of their securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. The company's actual performance could greatly differ from those described in any forward looking statements or announcements mentioned in our releases. A company's past performance does not guarantee future results. Further specific financial information, filings and disclosures as well as general investor information about the profiled companies, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website www.sec.gov and the Financial Industry Regulatory Authority (“FINRA”) website at www.finra.org.

The content in this release is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. This release may provide hyperlinks to third party websites or access to third party content. Pennystocktitans.com, its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does Pennystocktitans.com control, endorse, or guarantee any content found in such sites.

Pennystocktitans.com has been compensated $ 5000 from Awarness Consulting  which services include the issuance of this release and other opinions that we release concerning ofSolo Endoscopy  (OTC:SNDY). Pennystocktitans.com has not investigated the background of Awarness Consulting the hiring party, or  Solo Endoscopy  (OTC:SNDY). Anyone viewing this newsletter should assume Awarness Consulting or affiliates of  Awarness Consultingown shares of   Solo Endoscopy  (OTC:SNDY)...of which they plan to liquidate, and further understand that the liquidation of those shares may or may not negatively impact the share price. Pennystocktitans.com has received this amount as a production budget for advertising efforts and will retain amounts over and above the cost of production, copywriting services, mailing and other distribution expenses as a fee for our services. As such, our opinion is neither unbiased nor independent, and you should consider that when evaluating our statements on  Solo Endoscopy  (OTC:SNDY).